Vaccines – Therapeutics – Biosimilars

Successful clinical trials at EMA and US-FDA as well as marketing authorizations for products developed for our clients have been achieved for various biopharmaceuticals.

Production cell lines and processes developed at ARTES result in highly immunogenic vaccines with cost of goods of significantly less than 1 Euro per dose.

Biosimilar processes lead to authentic products complying to international pharmacopeia and are manufactured at extremely affordable cost of goods (< 50% of the originator).